CervoMed neflamapimod cuts NfL biomarker in nfvPPA Phase 2a

CervoMed has reported initial biomarker data from its Phase 2a trial of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA), showing a mean reduction in plasma neurofilament light chain (NfL) levels over the first 12 weeks of treatment. The results were presented as a late-breaking oral session at the 15th International Society of Frontotemporal Dementias Annual Meeting in Philadelphia on 12 October.

NfL is a protein released into the bloodstream when nerve cells are damaged and is widely used in neurodegenerative disease research as a measure of ongoing neuronal injury. A fall in plasma NfL during treatment is generally interpreted as a signal of reduced neurodegeneration, though it does not by itself confirm clinical benefit.

What the data show

The open-label phase enrolled 25 participants, of whom 72% had elevated NfL levels at baseline relative to the general population. Mean baseline NfL across the cohort was 45.7 pg/mL. Over 12 weeks, mean plasma NfL fell by approximately 3.1 pg/mL, with most of the decline occurring between weeks six and twelve. In a pre-specified exploratory subgroup of the 13 participants with baseline NfL at or above the cohort median, the mean decline was approximately 5.7 pg/mL, suggesting a stronger effect in those with greater underlying neurodegeneration at enrolment.

Levels of a second biomarker, glial fibrillary acidic protein (GFAP), were stable over the same period. The company reported that neflamapimod was generally well tolerated; one participant met protocol-defined criteria for discontinuation following an elevation in liver enzyme levels, which resolved after the drug was stopped. No bilirubin elevation was reported in that individual.

John Alam, chief executive of CervoMed, noted that NfL levels in nfvPPA typically rise over time in natural history studies, making the observed mean decline "particularly notable given NfL's long half-life." Ian Grant, assistant professor of neurology at Northwestern University's Feinberg School of Medicine and an investigator on the trial, described the reduction as "intriguing" while stressing that the results are early.

Market context and regulatory path

nfvPPA is a form of frontotemporal dementia most commonly associated with tau pathology. An estimated 10,000 to 15,000 people live with the condition in the United States and 15,000 to 20,000 in the European Union. There are currently no pharmacological treatments approved in either jurisdiction, a gap that has drawn growing attention from both academic centres and small-cap clinical-stage companies. Neflamapimod holds FDA Orphan Drug Designation for nfvPPA, which confers seven years of market exclusivity upon approval and may facilitate trial recruitment incentives.

The drug is an oral, blood-brain-barrier-penetrant small molecule that selectively inhibits p38 alpha MAP kinase, a pathway implicated in tau-driven neuronal injury. That mechanism distinguishes it from antibody-based anti-tau approaches currently in development by larger players, though head-to-head comparisons in nfvPPA remain premature at this stage.

CervoMed is targeting two near-term data readouts: 24-week biomarker results from this same trial are scheduled for the Clinical Trials on Alzheimer's Disease conference in November 2026, and topline clinical efficacy data are expected in the first quarter of 2027. The company is simultaneously seeking a strategic partner to advance neflamapimod into a Phase 3 trial in dementia with Lewy bodies, following alignment with the FDA on a potential registration pathway disclosed in November 2025. A first patient dosing in the EXPERTS-ALS trial, a separate neflamapimod programme in amyotrophic lateral sclerosis, is also planned before the end of 2026.

The open-label, uncontrolled design of the current data set limits interpretation; the 12-week double-blind randomised withdrawal period built into the trial is intended to provide a placebo-controlled read, which investors and clinicians will require before drawing firm conclusions about clinical utility.